← Back to Search

Other

Gly-low Cocktail for Obesity

Phase 1 & 2
Waitlist Available
Led By Marshall Stoller, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Obese individuals with BMI >27
Be older than 18 years old
Must not have
Must be younger than 50 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 1 year

Summary

This trial tests a pill called Gly-low, which is a mix of five safe compounds. It aims to help adults aged 50-70 with obesity by reducing harmful sugar-related compounds in their bodies. The goal is to lower food intake, weight gain, and improve overall health.

Who is the study for?
This trial is for adults under 50 years old with obesity, defined as having a body mass index (BMI) over 27. It aims to test if a special cocktail of compounds can help reduce their appetite and lower markers related to insulin resistance.
What is being tested?
The study is testing 'Gly-low', a mix including alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine against a placebo. Gly-low has shown promise in reducing food intake and weight in animal studies and may influence aging pathways.
What are the potential side effects?
Potential side effects are not detailed but could include reactions to the ingredients like stomach upset or allergic responses. Since it affects metabolic pathways, there might be changes in energy levels or other metabolic disturbances.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am obese with a BMI over 27.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 50 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in body mass index (BMI) from baseline to 1 year
Change in frailty from baseline to 1 year
Cognition
Secondary study objectives
Blood Marker Glucose for Aging and Insulin Resistance
Other study objectives
Elder Abuse

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: InterventionExperimental Treatment1 Intervention
MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
Group II: ControlPlacebo Group1 Intervention
sugar pill

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for obesity include pharmacologic agents like GLP-1 receptor agonists (e.g., semaglutide, liraglutide), which promote weight loss by enhancing satiety and reducing appetite. Dietary interventions, such as low-carbohydrate or Mediterranean diets, focus on macronutrient composition to reduce caloric intake and improve metabolic health. Exercise increases insulin sensitivity and energy expenditure. The Gly-low cocktail, which lowers methylglyoxal (MGO) levels, aims to reduce food intake and weight gain by targeting the molecular pathways that drive sugar addiction. Understanding these mechanisms helps obesity patients and their doctors choose the most effective treatment tailored to their metabolic and behavioral needs.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,570 Previous Clinical Trials
15,175,440 Total Patients Enrolled
34 Trials studying Obesity
11,500 Patients Enrolled for Obesity
Marshall Stoller, MDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

Gly-low (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05083546 — Phase 1 & 2
Obesity Research Study Groups: Control, Intervention
Obesity Clinical Trial 2023: Gly-low Highlights & Side Effects. Trial Name: NCT05083546 — Phase 1 & 2
Gly-low (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05083546 — Phase 1 & 2
Obesity Patient Testimony for trial: Trial Name: NCT05083546 — Phase 1 & 2
~67 spots leftby Dec 2025